A new prescription skin formula combines two of longevity science’s most recognizable molecules. The biology is plausible, and each ingredient has some human evidence. The exact combination being sold has not been shown in a published clinical trial.
Agency Skin announced a patent-pending product called Cell Repair Rx that pairs topical rapamycin with resveratrol. The company says the nightly formula targets inflammaging and supports firmer skin and improved elasticity. Its launch announcement does not disclose the concentrations of either ingredient or cite a trial of the finished product.
The rapamycin signal is interesting, but small
Rapamycin inhibits mTOR, a nutrient-sensing pathway involved in growth, protein turnover and aging biology. In a 2019 exploratory randomized study, adults older than 40 applied 10 micromolar rapamycin to one hand and vehicle to the other for six to eight months.
The treated hands showed lower p16INK4A, a marker associated with cellular senescence, more collagen VII, and improvements in clinical and histologic measures of skin aging. Those findings justify larger trials. They do not establish broad skin rejuvenation.
The study enrolled 36 people, but 19 discontinued or were lost to follow-up. Clinical analysis was available for a much smaller group, and biopsy comparisons involved only six participants. The within-person hand design was useful for controlling individual differences, but the sample was too small to define uncommon harms or durable benefit.
Resveratrol has a familiar evidence problem
Resveratrol has antioxidant and signaling effects in laboratory models, but its longevity reputation has repeatedly outrun human outcomes. We reviewed that history in What Happened to Resveratrol, the Longevity Molecule That Was Everywhere?
A 2025 double-blind randomized trial enrolled 134 women aged 40 or older and followed 122 who completed eight weeks. Participants received oral resveratrol, 1.5 percent topical resveratrol, both, or double placebo. Wrinkle improvement was statistically significant only for the combined oral and topical group versus placebo. Several other skin measures did not differ significantly. Some authors were employees of the ingredient company.
A separate skin penetration study found that topical resveratrol accumulated mainly in the outer stratum corneum while showing local antioxidant activity. That supports topical delivery as a concept, not a claim that it slows skin aging.
The missing trial is the product itself
No published human clinical trial was located for Agency Skin’s exact rapamycin-resveratrol combination. Combining two biologically active ingredients can change stability, penetration, dosing and irritation. Evidence for ingredient A and ingredient B cannot simply be added together as evidence for product A plus B.
The phrase “skin longevity” also needs discipline. Smoother appearance, collagen markers or lower p16 can be worthwhile endpoints, but none directly demonstrates that skin remains healthier for longer, resists disease or preserves function over years.
Safety and regulation
Rapamycin is an immunosuppressive drug when used systemically, although topical exposure can be much lower. Local irritation, acne-like reactions, infection risk and variable absorption deserve attention, especially with long-term use or use on damaged skin. A prescription and clinician oversight are appropriate, but they do not replace product-specific safety data.
The FDA distinguishes cosmetic appearance claims from claims that a product changes the structure or function of skin. Products making drug claims must meet drug requirements. Marketing language alone does not tell a consumer what evidence the finished formulation has passed.
Bottom line: Topical rapamycin is a credible research lead, and resveratrol has limited human skin data. Calling their untested combination a demonstrated skin-longevity treatment goes beyond the published evidence. The most useful next step is a preregistered, adequately powered trial of the actual formula with disclosed concentrations, adverse-event reporting and clinically meaningful endpoints.
Sources: Agency Skin announcement; topical rapamycin trial; resveratrol trial; FDA guidance